Carbetocin vs. Oxytocin Plus Misoprostol Compared for Intraoperative Blood Loss in Elective Cesarean Section
Background
Excessive intraoperative blood loss during Cesarean Section (CS) remains a significant concern, contributing to maternal morbidity and mortality. Current standard-of-care often involves Oxytocin to promote uterine contraction and minimize bleeding. However, some patients may still experience substantial blood loss, necessitating additional uterotonics. Emerging evidence suggests Carbetocin, a longer-acting oxytocin analog, might offer superior efficacy or a more favorable side effect profile, potentially reducing blood loss and the need for rescue interventions.
Study Design
This Phase 4 randomized controlled trial (NCT05664659) enrolled 90 women undergoing elective Cesarean Section. Participants were divided into two groups: one receiving Oxytocin plus buccal Misoprostol, and the other receiving Carbetocin. The primary endpoint was estimated intraoperative blood loss. The study aimed to compare the effectiveness of these two uterotonic regimens in reducing bleeding during the surgical procedure.
Why It Matters
If Carbetocin proves superior or non-inferior to the combination of Oxytocin and Misoprostol in reducing blood loss during Cesarean Section, it could streamline protocols and potentially improve maternal outcomes. A single, longer-acting agent like Carbetocin might simplify administration and reduce the need for multiple medications. This research could inform updated clinical guidelines for uterotonic prophylaxis in elective CS, potentially leading to safer deliveries and reduced complications for mothers worldwide. The findings, once available, will clarify whether a shift in current practice is warranted.
carbetocin
oxytocin
misoprostol
cesarean-section
blood-loss
obstetrics